ArticleSisli Etfal Hastanesi tip bulteni2026
A Novel Marker in Hypogonadal Hypogonadism: Apelin.
Article in Sisli Etfal Hastanesi tip bulteni, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Apelin is a recently identified adipokine with pleiotropic actions in cardiovascular regulation, metabolic homeostasis, bone remodeling, and reproductive physiology. Through binding to the apelin receptor (APJ), apelin has been shown to influence gonadotropin-releasing hormone (GnRH) secretion, which is essential for the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Given its potential role in the hypothalamic-pituitary-gonadal (HPG) axis, alterations in circulating apelin may contribute to hypogonadotropic hypogonadism (HH). This study aimed to investigate whether serum apelin concentrations are altered in patients with HH and to evaluate its potential relevance as a complementary biomarker in the diagnostic approach to HH. Methods: A total of 60 participants were enrolled: 30 newly diagnosed HH patients (untreated for at least one year, with no comorbid chronic diseases) and 30 age- and body mass index (BMI)-matched healthy controls. Individuals with BMI<20 or BMI>30 were excluded to minimize confounding metabolic influences on apelin secretion. Following overnight fasting, venous blood samples were obtained for complete biochemical and hormonal profiles. Serum apelin levels were measured using a validated human ELISA kit (SunRed Biotechnology, China; intra- and inter-assay coefficients of variation<10%). Statistical analysis was performed using SPSS 17.0. Results: Apelin concentrations were significantly lower in HH patients compared with healthy controls (median 35.2ng/L vs. 63.3ng/L, p=0.046). ROC analysis yielded an area under the curve (AUC) of 0.65, with a sensitivity of 76% and a specificity of 64%. Conclusion: These findings demonstrate reduced circulating apelin concentrations in HH, supporting the hypothesis of its involvement in GnRH regulation and the pathogenesis of hypogonadism. Although its diagnostic accuracy is modest, apelin may complement traditional hormonal markers. Further multicenter studies and mechanistic research are required to validate these observations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.